Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Potentia Pharmaceuticals Awarded Phase I STTR Grants from the National Eye Institute
June 1, 2006
Louisville, Ky. – Potentia Pharmaceuticals, together with academic collaborators, received two Phase I STTR grants from the National Eye Institute to develop new, less invasive delivery technologies for ocular therapeutics. The first grant, involving a collaboration with the Lions Eye Center of the University of Louisville, investigates the use of disease-targeted polymeric nanoparticles that could be administered intravenously. The second program will explore the use of a local controlled-release transscleral delivery vehicle in collaboration with the University of Arkansas for Medical Sciences. These two programs address the important aspect of delivery of drugs to the back of the eye, one of the major obstacles currently facing many promising therapies for ocular diseases.